Your browser doesn't support javascript.
Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.
Cucchiari, David; Egri, Natalia; Bodro, Marta; Herrera, Sabina; Del Risco-Zevallos, Jimena; Casals-Urquiza, Joaquim; Cofan, Frederic; Moreno, Asunción; Rovira, Jordi; Banon-Maneus, Elisenda; Ramirez-Bajo, Maria J; Ventura-Aguiar, Pedro; Pérez-Olmos, Anna; Garcia-Pascual, Marta; Pascal, Mariona; Vilella, Anna; Trilla, Antoni; Ríos, José; Palou, Eduard; Juan, Manel; Bayés, Beatriu; Diekmann, Fritz.
  • Cucchiari D; Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain.
  • Egri N; Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Bodro M; Department of Immunology, Hospital Clínic, Barcelona, Spain.
  • Herrera S; Department of Infectious Diseases, Hospital Clínic, Barcelona, Spain.
  • Del Risco-Zevallos J; Department of Infectious Diseases, Hospital Clínic, Barcelona, Spain.
  • Casals-Urquiza J; Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain.
  • Cofan F; Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain.
  • Moreno A; Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain.
  • Rovira J; Department of Infectious Diseases, Hospital Clínic, Barcelona, Spain.
  • Banon-Maneus E; Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Ramirez-Bajo MJ; Red de Investigación Renal (REDINREN), Madrid, Spain.
  • Ventura-Aguiar P; Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Pérez-Olmos A; Red de Investigación Renal (REDINREN), Madrid, Spain.
  • Garcia-Pascual M; Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Pascal M; Red de Investigación Renal (REDINREN), Madrid, Spain.
  • Vilella A; Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain.
  • Trilla A; Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Ríos J; Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain.
  • Palou E; Department of Nephrology and Kidney Transplantation, Hospital Clínic, Barcelona, Spain.
  • Juan M; Department of Immunology, Hospital Clínic, Barcelona, Spain.
  • Bayés B; Immunoal·lergia Clínica Respiratoria i Experimental (IRCE), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Diekmann F; Red Nacional de Alergia, Asma, Reacciones Adversas y Alérgicas (ARADyAL), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Am J Transplant ; 21(8): 2727-2739, 2021 08.
Article in English | MEDLINE | ID: covidwho-1243589
ABSTRACT
According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and 2 weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine. At baseline, 31 patients (20.9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-pre-immunized, while 117 (79.1%) patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S-ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with antithymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Kidney Transplantation / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Am J Transplant Journal subject: Transplantation Year: 2021 Document Type: Article Affiliation country: Ajt.16701

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Kidney Transplantation / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Am J Transplant Journal subject: Transplantation Year: 2021 Document Type: Article Affiliation country: Ajt.16701